IMMERVISION
23.11.2021 20:38:09 CET | Business Wire | Press release
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, today announced its ultra-wide lenses will be integrated into IONODES’ PERCEPT body camera. This collaboration will give businesses and the general public greater peace of mind, by providing physical security workers with a body camera that can effectively capture in real-time any potential security threats or issues in high resolution and never miss a detail through a Panomorph lens with 180° field of view.
“In the physical security industry, the challenge that most companies face with body worn cameras is that the video fails to effectively capture what’s occurring due to narrow field-of-view and poor image resolution,” said Eric Tasso, President at IONODES. “By selecting Immervision technology and their team of experts, we are providing security, industrial and commercial organizations with the highest-quality wearable cameras to improve safety, enhance security, optimize business processes and provide transparency."
IONODES’ body-worn IoT device is the first of a series of products that combines Immervision’s ultra-wide-angle lens, image processing and sensor technology with IONODES 4K camera, and connects to Wi-Fi, Bluetooth and LTE. IONODES’ device integrates seamlessly with a GPS receiver and 9-axis motion sensor, allowing users to closely follow the field of view in real-time, to stabilize the image and provide location tracking to users, whether for security, prevention, monitoring or entertainment applications
“Over the last 20 years, Immervision has focused on cultivating and perfecting its expertise in advanced vision systems, giving devices in industries such as physical security the ability to truly perceive the world around them,” said Pascale Nini, President and CEO at Immervision. “Immervision and IONODES are deeply committed to offering the best vision systems in the market for security and surveillance, and we look forward to continuing to make more innovative strides in developing high-quality wearable camera devices and AI-based vision systems.”
About Immervision
With over 20 years of innovation, Immervision creates solutions to see beyond human vision. To enable a machine to exceed human vision and unlock the full potential of AI, we develop advanced vision systems combining optics, image processing, and sensor fusion technology. Our Deep Seeing Technology enables hardware and software manufacturers to equip smart devices with the best vision possible for any industry including transportation, security, defense, computing, robotics, and more. www.immervision.com
About IONODES
IONODES is focused on pushing the boundaries of video technology, developing the latest in IP video storage, management and display solutions. Its experience in IP video and strong partnerships with industry leaders deliver innovative products designed to enhance people’s lifestyle while ensuring their safety and security.
IONODES designs, develops, and manufactures IP-based video solutions optimized for use in video surveillance. Its products include smart IP video appliances, such as body worn cameras, video encoders, video wall appliances, recording servers and workstations. The company offers its products through distributors, resellers, and representatives worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006095/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom